CClinicalTrials.gg
RecruitingNCT03911492CASPERUpdated Jul 3, 2023

Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

An interventional study of SCPP Management => 65 mmHg in Acute Spinal Cord Injury, Acute Spinal Paralysis and Spinal Cord Injuries, sponsored by University of British Columbia. Recruiting at 8 sites in 2 countries. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Aug 2019; still recruiting 7 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
17 Years and older
Sex
All
01

Study summary

This multicenter study will enroll 100 patients with acute traumatic cervical and thoracic SCI who have a lumbar intrathecal catheter inserted within 24 hours of their injury. The lumbar intrathecal catheter will be inserted pre-operatively for the measurement of ITP and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between MAP and the ITP.

There are two important distinct yet related objectives in this prospective interventional study.

  1. Determine the effect of SCPP maintenance ≥ 65 mmHg in acute SCI on neurologic recovery as measured by ASIA Impairment Scale (AIS) grade conversion and motor score improvement.
  2. Collect CSF and blood samples for the measurement of neurochemical biomarkers and storage for future biomarker discovery and validation studies.
Read the detailed description

Objective 1. To determine if actively maintaining an SCPP of at least 65 mmHg with a combination of MAP augmentation and CSF drainage promotes better neurologic recovery than routine hemodynamic management that focuses solely on MAP augmentation.

Objective 2. To determine if actively maintaining an SCPP of at least 65 mmHg with a combination of MAP augmentation and CSF drainage will allow for a reduction in the usage of vasopressors in acute SCI.

Objective 3. To determine the feasibility of draining CSF to reduce ITP in the acute post-injury setting, when the cord may be swollen against the dura causing subarachnoid space occlusion at the injury site.

Objective 4. To determine if there are complications associated with the installation of the intrathecal catheter and drainage of CSF in the acute SCI patient.

02

Conditions studied

  • Acute Spinal Cord Injury
  • Acute Spinal Paralysis
  • Spinal Cord Injuries
  • SPINAL Fracture

Keywords

  • SCI
  • Spinal Cord Injury
  • CSF
  • Biomarker
  • CSF pressure
  • Traumatic SCI
  • Perfusion pressure
03

In context

Spinal Cord Injuries

1,948 studies on the registry are indexed under Spinal Cord Injuries; 505 are open to participants now.

This study's planned enrollment of 100 is above the median of 24 across 1,566 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or Female ≥ 17 (or the provincial age of majority - depending on local REB guidelines)
  • Complete (AIS A) or incomplete (AIS B, C) acute traumatic spinal cord injury.
  • Bony spinal levels between C0 and T12 inclusive.
  • Blunt (non-penetrating) spinal cord injury treated either surgically or non-surgically
  • Lumbar intrathecal catheter to be inserted as part of clinical hemodynamic management and CSF sample collected within 48 hours of injury
  • Initial blood sample collected within 24 hours of injury

Exclusion criteria

Exclusion Criteria:

  • Motor incomplete spinal cord injury AIS D (i.e. at least half (half or more) of the key muscle functions below the neurological level of injury (NLI) have a muscle grade greater than or equal to 3/5)
  • Spinal cord injury with sensory deficit only (i.e. no motor deficit)
  • Penetrating spinal cord injury (including gunshot wounds)
  • Isolated radiculopathy
  • Isolated cauda equina injury or spinal injury below L1
  • Associated injury (soft tissue or bony) to the lumbar spine where the intrathecal catheter would be placed
  • Associated traumatic conditions that would interfere with the outcome assessment (e.g., traumatic brain injury, chest, pelvis, abdomen, or femur injury requiring operative intervention)
  • Pre-existing neurodegenerative disorder, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis
  • Pre-existing thromboembolic disease or coagulopathy, such as hemophilia, von Willebrand disease
  • Presence of systemic disease that might interfere with patient safety, compliance or evaluation of the condition under study (e.g., clinically significant cardiac disease, HIV, Hep B or C) HTLV-1
  • Pre-existing inflammatory or autoimmune disorder (e.g. rheumatoid arthritis, systemic lupus, psoriasis, or ankylosing spondylitis
  • Any other medical condition that in the investigator's opinion would render the protocol procedures dangerous or impair the ability of the patient to receive protocol therapy
  • Female patients who are pregnant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    SCP Pressure Management

    Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg.

    Procedure: SCPP Management => 65 mmHg

Interventions

  • ProcedureSCPP Management => 65 mmHg

    A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.

06

What researchers measure

Primary outcomes

  1. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Examination

    Neurologic recovery over time will be measured using the ISNCSCI examination - at Baseline, Days 1-7, and months 3, 6 and 12. Our primary outcome measure will be the change in total motor score at 6 months post-injury (a time point at which most motor recovery has occurred and is commonly used in acute SCI clinical trials).

    Time frame: 12 months

Secondary outcomes

  1. Levels of specific biochemical markers in CSF and Blood

    CSF and blood samples will be obtained from the intrathecal catheter at 8-hour intervals, three times daily, for 7 days. These samples will be markers that correlate with injury severity and predict neurological outcome.

    Time frame: 7 days

  2. Spinal Cord Perfusion Pressure (SCPP)

    SCPP will be calculated as the difference between the mean arterial pressure and intrathecal pressure. The MAP and ITP will recorded over 7 days post injury.

    Time frame: 7 days

07

Study locations

8 of 8 sites recruiting
  • Zuckerberg San Francisco General Hospital and Trauma Center
    San Francisco, California 94110, United States
    • Xuan Duong Fernandez · Contact
    • Anthony DiGiorgio, MD · Principal investigator
    Recruiting
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    • Dulce Maroni · Contact
    • Jamie Wilson, MD · Principal investigator
    Recruiting
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
    • Amal Alchbli · Contact
    • Christian Ricks, MD · Principal investigator
    Recruiting
  • University Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    • David Okonkwo · Principal investigator
    Recruiting
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
    • Allan Aludino, Research Program Manager · Contact · Allan.Aludino@vch.ca · 1-604-875-4111
    • Brian Kwon, MD, PhD · Principal investigator
    Recruiting
  • Halifax Infirmary - QEII
    Halifax, Nova Scotia B3K 4N1, Canada
    • Sean Christie, MD · Principal investigator
    Recruiting
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
    • Cecilia He · Contact
    • Jeff Wilson, MD · Principal investigator
    Recruiting
  • Hopital Du Sacre-Coeur de Montreal
    Montreal, Quebec H4J1C5, Canada
    • Pascal Mputu · Contact
    • Jean-Marc Mac-Thiong, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03911492
Lead sponsor
University of British Columbia
Collaborators
Rick Hansen Institute
Responsible party
Brian Kwon (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Apr 11, 2019
Start date
Aug 31, 2019
Primary completion
Mar 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jul 3, 2023

Study contacts

Allan Aludino
Contact
allan.aludino@vch.ca
604-875-4111 ext. 61689
Brian Kwon, MD, PhD
principal investigator · University of British Columbia, Faculty of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion